Abstract
Overexpression of the leucine-rich, glioma-inactivated 1 (LGI1) gene in neuroblastoma cells inhibited proliferation and efficiently induced apoptosis. Cell clones stably transfected with LGI1 cDNA showed greater mortality during a period of serum starvation in comparison with control cells stably transfected with empty vector. This observation suggested hindrance of the PI3K/Akt pathway, a central transducer of survival stimuli elicited by serum growth factors. Treatment with inhibitors of PI3K significantly increased the death of control cells but substantially failed to influence LGI1 cell death, which was greatest independently of the presence of inhibitors. Blockage of the PI3K/Akt pathway in LGI1 cells was confirmed by the lack of serum-induced Akt phosphorylation, in contrast with the strong response of control cells. Instead, serum-induced phosphorylation of ERK1/2 was not impaired by the expression of LGI1. This study showed that overexpression of LGI1 caused neuroblastoma cell death by blocking activation of the PI3K/Akt pathway. Thus, the possibility of upregulating LGI1 expression may be a novel strategy in suppressing oncogenesis and metastasis sustained by excessive activation of the PI3K/Akt pathway.
Keywords: Neuroblastoma, leucine-rich, glioma-inactivated 1 (LGI1), phosphoinositide 3-kinase (PI3K), cell death
Current Signal Transduction Therapy
Title: LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Volume: 3 Issue: 2
Author(s): Nadia Gabellini and Valentina Masola
Affiliation:
Keywords: Neuroblastoma, leucine-rich, glioma-inactivated 1 (LGI1), phosphoinositide 3-kinase (PI3K), cell death
Abstract: Overexpression of the leucine-rich, glioma-inactivated 1 (LGI1) gene in neuroblastoma cells inhibited proliferation and efficiently induced apoptosis. Cell clones stably transfected with LGI1 cDNA showed greater mortality during a period of serum starvation in comparison with control cells stably transfected with empty vector. This observation suggested hindrance of the PI3K/Akt pathway, a central transducer of survival stimuli elicited by serum growth factors. Treatment with inhibitors of PI3K significantly increased the death of control cells but substantially failed to influence LGI1 cell death, which was greatest independently of the presence of inhibitors. Blockage of the PI3K/Akt pathway in LGI1 cells was confirmed by the lack of serum-induced Akt phosphorylation, in contrast with the strong response of control cells. Instead, serum-induced phosphorylation of ERK1/2 was not impaired by the expression of LGI1. This study showed that overexpression of LGI1 caused neuroblastoma cell death by blocking activation of the PI3K/Akt pathway. Thus, the possibility of upregulating LGI1 expression may be a novel strategy in suppressing oncogenesis and metastasis sustained by excessive activation of the PI3K/Akt pathway.
Export Options
About this article
Cite this article as:
Gabellini Nadia and Masola Valentina, LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase, Current Signal Transduction Therapy 2008; 3 (2) . https://dx.doi.org/10.2174/157436208784223125
DOI https://dx.doi.org/10.2174/157436208784223125 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Delivery of Large Genomic DNA Inserts > 100 kb Using HSV-1 Amplicons
Current Gene Therapy Vascular microRNAs
Current Drug Targets Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Current Molecular Medicine Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy Editorial (Thematic Issue: PET/CT in External Beam Radiation Therapy Dose Planning)
Current Radiopharmaceuticals Liposome-Encapsulated Photosensitizers Against Bacteria
Recent Patents on Anti-Infective Drug Discovery A Discussion Regarding the Application of the Hertz Contact Theory on Biological Samples in AFM Nanoindentation Experiments
Micro and Nanosystems Editorial [Hot Topic: Mechanisms of Drug Sensitivity and Resistance in Cancer (Guest Editor: Lorraine ODriscoll)]
Current Cancer Drug Targets The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design The Urokinase Receptor Interactome
Current Pharmaceutical Design